937678-86-9

Upstream product

• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 824-94-2 p-methoxybenzyl chloride 
• 2746-25-0 p-Methoxybenzyl bromide 

Downstream Products

• 1242846-76-9 (4-(4-methoxybenzyloxy)-3-bromophenyl)-N-methylmethanamine 
• 1256644-98-0 C₁₉H₁₉BrN₄O₂ 
• 1256645-18-7 C₂₄H₂₁BrN₂O₂ 
• 1242845-54-0 (S)-2-(2-(3-trifluoromethylphenyl)-4-((4-fluoro-N-methylphenylsulfonamido)methyl)phenoxy)propanoic acid 
• 1242846-80-5 benzyl-(R)-2-(2-(3-trifluoromethylphenyl)-4-((4-fluoro-N-methylphenylsulfonamido)methyl)phenoxy)propanate 
• 1242846-05-4 (R)-2-(2-(3-trifluoromethylphenyl)-4-((4-fluoro-N-methylphenylsulfonamido)methyl)phenoxy)propanoic acid 
• 1242846-25-8 2-(2-(3-trifluoromethylphenyl)-4-((4-fluoro-N-methylphenylsulfonamido)methyl)phenoxy)-2-methylpropanoic acid 
• 1242846-79-2 N-(3-(3-trifluoromethylphenyl)-4-hydroxybenzyl)-4-fluoro-N-methylbenzenesulfonamide 
• 1242846-78-1 N-(4-(4-methoxybenzyloxy)-3-(3-trifluoromethylphenyl)benzyl)-4-fluoro-N-methylbenzenesulfonamide 
• 1242846-77-0 N-(4-(4-methoxybenzyloxy)-3-bromobenzyl)-4-fluoro-N-methylbenzenesulfonamide 
• 1242846-81-6 t-butyl-(S)-2-(2-(3-trifluoromethylphenyl)-4-((4-fluoro-N-methylphenylsulfonamido)methyl)phenoxy)propanate 
• 83030-53-9 3-bromotyramine p-methoxybenzyl ether 
• 75513-48-3 prebastadin 1 
• 83030-54-0 3-[3-Bromo-5-(2-bromo-4-{2-{2-[3-bromo-4-(4-methoxy-benzyloxy)-phenyl]-ethylcarbamoyl}-2-[(E)-hydroxyimino]-ethyl}-phenoxy)-4-hydroxy-phenyl]-N-{2-[3-bromo-4-(4-methoxy-benzyloxy)-phenyl]-ethyl}-2-[(E)-hydroxyimino]-propionamide 

Relevant academic research and scientific papers

BIARYL OXYACETIC ACID COMPOUNDS

Some embodiments of the present invention include novel phenoxyacetic acids useful for the prevention and treatment of inflammatory disorders, including those affecting the respiratory system and skin. Some compounds provided include those of the general formula (I), and compounds of general formula (Ia).

BIARYL OXYACETIC ACID COMPOUNDS

The present invention provides biaryl oxyacetic acid compounds which may be useful for treating inflammatory disorders, including disorders affecting the respiratory system and skin. The compounds provided include those of the general formula I.

Synthesis of 5-substituted benzyl-2,4-diamino pyrimidine derivatives as c-Fms kinase inhibitors

A serials of novel 5-substituted benzyl-2,4-diamino pyrimidine derivatives have been synthesized and evaluated as inhibitors of c-Fms kinase by the standard MTT method. The results showed that compound 15,5-[3-methoxy-4-(pyridine-3-yl)benzyl]-2,4-diamino pyrimidine, had an IC50 of 1.45μmol/L in inhibiting the proliferation of M-CSF-dependent myeloid leukemia cells in mice (NFS-60), which was similar with GW2580, a selective inhibitor of c-Fms kinase.

TOTAL SYNTHESIS OF BASTADINS

Bastadins-1, -2 and -3, the novel metabolites originated from four bromotyrosine units, were synthesized, and each geometry at the oxime C=N double bonds was unambiguously determined to be anti.